All In Biotech

Drug Trial Radar · NCT07679893

Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial of the Efficacy and Safety of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis Followed by an Open-Label Extension

Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 153 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

153

Planned (sponsor's estimate)

Start

May 15, 2026

Primary completion

Dec 30, 2027

Study completion Jun 2028

Sponsor

Lead sponsor
Mannkind CorporationIndustry
Sponsor type
Industry
First posted
Jul 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a randomized, double-blind, placebo-controlled study evaluating the safety and preliminary efficacy of inhaled Nintedanib Dry Powder Inhalation (DPI) in adults with idiopathic pulmonary fibrosis (IPF). Participants are randomized to receive either 2 mg BID, 4 mg BID, or matching placebo for 12 weeks, followed by a 24-week open-label extension in which all participants receive active treatment. The primary focus is on safety-particularly bronchospasm events, lung function changes (FEV1, FEV1/FVC), and adverse event rates and assessing the effectiveness of nintedanib DPI in treating IPF.

Conditions

  • Idiopathic Pulmonary Fibrosis
  • Idiopathic Pulmonary Fibrosis (IPF)

Interventions

  • Nintedanib Dry Powder InhalationDrug

    Nintedanib DPI is a dry powder nintedanib formulation for oral inhalation.

  • PlaceboDrug

    Placebo oral inhalation powder

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and EfficacyTime frame: From enrollment to the end of randomized treatment at 12 weeks
  2. Events of clinical bronchospasmTime frame: From enrollment to the end of open-label treatment at 36 weeks
  3. FEV1 changeTime frame: From enrollment to the end of open-label treatment at 36 weeks
  4. Spirometry ChangeTime frame: enrollment to end of open label at 36 weeks
  5. Study Drug DiscontinuationTime frame: From enrollment to the end of open-label treatment at 36 weeks
  6. Study Drug Dose ReductionsTime frame: From enrollment to the end of open-label treatment at 36 weeks
  7. Adverse EventsTime frame: From enrollment to the end of open-label treatment at 36 weeks
  8. Related Adverse EventsTime frame: From enrollment to the end of open-label treatment at 36 weeks
  9. Serious Adverse EventsTime frame: From enrollment to the end of open-label treatment at 36 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Trial Management Group Inc

    Windsor, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.